Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study
Identifieur interne : 000172 ( Main/Corpus ); précédent : 000171; suivant : 000173Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study
Auteurs : Jane A. Driver ; Giancarlo Logroscino ; Linda Lu ; J Michael Gaziano ; Tobias KurthSource :
- BMJ [ 0959-8138 ] ; 2011.
Abstract
Objective To evaluate the relation between Parkinson’s disease and prior use of non-steroidal anti-inflammatory drugs (NSAIDs) in a large cohort of men. Design Case-control analysis nested in the Physicians’ Health Study. Participants 22 007 male physicians aged 40–84 years without indications for or contraindications to regular NSAID use and free of Parkinson’s disease at baseline. Cases and controls were matched by age alone or by age and scores for confounders (comorbidity and indicators of NSAID use). Up to five controls were matched to each of 616 cases by age and 565 cases by age and confounder scores. Setting United States. Main outcome measures Odds of having been exposed to prior non-aspirin NSAID or aspirin use by participants with Parkinson’s disease and by their controls in each case-control set. Results Participants who had ever used non-aspirin NSAIDs had an increased risk of Parkinson’s disease (odds ratio 1.28 (95% CI 1.05 to 1.56) in the age matched group but not in the group also matched on confounder scores (odds ratio 1.17 (0.94 to 1.46)). There was an increased risk of Parkinson’s disease in men who had 1–2 years of regular non-aspirin NSAID use (odds ratio 1.35 (1.07 to 1.70)), a finding that remained significant after matching for confounder scores as well (odds ratio 1.35 (1.05 to 1.75)). In contrast, the significant association of use of non-aspirin NSAIDs for ≥5 years (odds ratio 1.48 (1.05 to 2.09)) in the age matched group was entirely attenuated in the group also matched on confounder scores (1.03 (0.70 to 1.53)). There was also a suggestion that men who regularly used aspirin had an increased risk of Parkinson’s disease. Positive associations between non-aspirin NSAID or aspirin and risk of Parkinson’s disease tended to disappear when analyses were limited to drug use ≥5 years before the disease diagnosis. Conclusions This case-control study did not find evidence that NSAID use reduces Parkinson’s disease risk. The positive associations observed between NSAID use and Parkinson’s disease might have been due to confounding by indication as the use was clustered in the few years before disease diagnosis.
Url:
DOI: 10.1136/bmj.d198
Links to Exploration step
ISTEX:EA84488FD2F1E76778E328DDFA4D82BE58E74696Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study</title><author><name sortKey="Driver, Jane A" sort="Driver, Jane A" uniqKey="Driver J" first="Jane A" last="Driver">Jane A. Driver</name><affiliation><mods:affiliation>Geriatric Research, Education and Clinical Center, VA Boston Healthcare System; Boston MA, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</mods:affiliation></affiliation><affiliation><mods:affiliation>Massachusetts Veterans Epidemiology Research Information Center, VA Boston Healthcare System</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jdriver@partners.org</mods:affiliation></affiliation></author><author><name sortKey="Logroscino, Giancarlo" sort="Logroscino, Giancarlo" uniqKey="Logroscino G" first="Giancarlo" last="Logroscino">Giancarlo Logroscino</name><affiliation><mods:affiliation>Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy</mods:affiliation></affiliation></author><author><name sortKey="Lu, Linda" sort="Lu, Linda" uniqKey="Lu L" first="Linda" last="Lu">Linda Lu</name><affiliation><mods:affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</mods:affiliation></affiliation></author><author><name sortKey="Gaziano, J Michael" sort="Gaziano, J Michael" uniqKey="Gaziano J" first="J Michael" last="Gaziano">J Michael Gaziano</name><affiliation><mods:affiliation>Geriatric Research, Education and Clinical Center, VA Boston Healthcare System; Boston MA, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</mods:affiliation></affiliation><affiliation><mods:affiliation>Massachusetts Veterans Epidemiology Research Information Center, VA Boston Healthcare System</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Preventive Medicine, Brigham and Women’s Hospital</mods:affiliation></affiliation></author><author><name sortKey="Kurth, Tobias" sort="Kurth, Tobias" uniqKey="Kurth T" first="Tobias" last="Kurth">Tobias Kurth</name><affiliation><mods:affiliation>Division of Preventive Medicine, Brigham and Women’s Hospital</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM Unit 708—Neuroepidemiology and UPMC University Paris 06, Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EA84488FD2F1E76778E328DDFA4D82BE58E74696</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1136/bmj.d198</idno><idno type="url">https://api.istex.fr/document/EA84488FD2F1E76778E328DDFA4D82BE58E74696/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000172</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study</title><author><name sortKey="Driver, Jane A" sort="Driver, Jane A" uniqKey="Driver J" first="Jane A" last="Driver">Jane A. Driver</name><affiliation><mods:affiliation>Geriatric Research, Education and Clinical Center, VA Boston Healthcare System; Boston MA, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</mods:affiliation></affiliation><affiliation><mods:affiliation>Massachusetts Veterans Epidemiology Research Information Center, VA Boston Healthcare System</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jdriver@partners.org</mods:affiliation></affiliation></author><author><name sortKey="Logroscino, Giancarlo" sort="Logroscino, Giancarlo" uniqKey="Logroscino G" first="Giancarlo" last="Logroscino">Giancarlo Logroscino</name><affiliation><mods:affiliation>Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy</mods:affiliation></affiliation></author><author><name sortKey="Lu, Linda" sort="Lu, Linda" uniqKey="Lu L" first="Linda" last="Lu">Linda Lu</name><affiliation><mods:affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</mods:affiliation></affiliation></author><author><name sortKey="Gaziano, J Michael" sort="Gaziano, J Michael" uniqKey="Gaziano J" first="J Michael" last="Gaziano">J Michael Gaziano</name><affiliation><mods:affiliation>Geriatric Research, Education and Clinical Center, VA Boston Healthcare System; Boston MA, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</mods:affiliation></affiliation><affiliation><mods:affiliation>Massachusetts Veterans Epidemiology Research Information Center, VA Boston Healthcare System</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Preventive Medicine, Brigham and Women’s Hospital</mods:affiliation></affiliation></author><author><name sortKey="Kurth, Tobias" sort="Kurth, Tobias" uniqKey="Kurth T" first="Tobias" last="Kurth">Tobias Kurth</name><affiliation><mods:affiliation>Division of Preventive Medicine, Brigham and Women’s Hospital</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM Unit 708—Neuroepidemiology and UPMC University Paris 06, Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">BMJ</title><title level="j" type="abbrev">BMJ</title><idno type="ISSN">0959-8138</idno><idno type="eISSN">1468-5833</idno><imprint><publisher>British Medical Journal Publishing Group</publisher><date type="published" when="2011">2011</date><biblScope unit="volume">342</biblScope></imprint><idno type="ISSN">0959-8138</idno></series><idno type="istex">EA84488FD2F1E76778E328DDFA4D82BE58E74696</idno><idno type="DOI">10.1136/bmj.d198</idno><idno type="href">bmj-342-bmj-d198.pdf</idno><idno type="ArticleID">drij761171</idno><idno type="local">bmj;342/jan20_1/d198</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0959-8138</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Objective To evaluate the relation between Parkinson’s disease and prior use of non-steroidal anti-inflammatory drugs (NSAIDs) in a large cohort of men. Design Case-control analysis nested in the Physicians’ Health Study. Participants 22 007 male physicians aged 40–84 years without indications for or contraindications to regular NSAID use and free of Parkinson’s disease at baseline. Cases and controls were matched by age alone or by age and scores for confounders (comorbidity and indicators of NSAID use). Up to five controls were matched to each of 616 cases by age and 565 cases by age and confounder scores. Setting United States. Main outcome measures Odds of having been exposed to prior non-aspirin NSAID or aspirin use by participants with Parkinson’s disease and by their controls in each case-control set. Results Participants who had ever used non-aspirin NSAIDs had an increased risk of Parkinson’s disease (odds ratio 1.28 (95% CI 1.05 to 1.56) in the age matched group but not in the group also matched on confounder scores (odds ratio 1.17 (0.94 to 1.46)). There was an increased risk of Parkinson’s disease in men who had 1–2 years of regular non-aspirin NSAID use (odds ratio 1.35 (1.07 to 1.70)), a finding that remained significant after matching for confounder scores as well (odds ratio 1.35 (1.05 to 1.75)). In contrast, the significant association of use of non-aspirin NSAIDs for ≥5 years (odds ratio 1.48 (1.05 to 2.09)) in the age matched group was entirely attenuated in the group also matched on confounder scores (1.03 (0.70 to 1.53)). There was also a suggestion that men who regularly used aspirin had an increased risk of Parkinson’s disease. Positive associations between non-aspirin NSAID or aspirin and risk of Parkinson’s disease tended to disappear when analyses were limited to drug use ≥5 years before the disease diagnosis. Conclusions This case-control study did not find evidence that NSAID use reduces Parkinson’s disease risk. The positive associations observed between NSAID use and Parkinson’s disease might have been due to confounding by indication as the use was clustered in the few years before disease diagnosis.</div></front></TEI><istex><corpusName>bmj</corpusName><author><json:item><name>Jane A Driver</name><affiliations><json:string>Geriatric Research, Education and Clinical Center, VA Boston Healthcare System; Boston MA, USA</json:string><json:string>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</json:string><json:string>Massachusetts Veterans Epidemiology Research Information Center, VA Boston Healthcare System</json:string><json:string>E-mail: jdriver@partners.org</json:string></affiliations></json:item><json:item><name>Giancarlo Logroscino</name><affiliations><json:string>Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy</json:string></affiliations></json:item><json:item><name>Linda Lu</name><affiliations><json:string>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</json:string></affiliations></json:item><json:item><name>J Michael Gaziano</name><affiliations><json:string>Geriatric Research, Education and Clinical Center, VA Boston Healthcare System; Boston MA, USA</json:string><json:string>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</json:string><json:string>Massachusetts Veterans Epidemiology Research Information Center, VA Boston Healthcare System</json:string><json:string>Division of Preventive Medicine, Brigham and Women’s Hospital</json:string></affiliations></json:item><json:item><name>Tobias Kurth</name><affiliations><json:string>Division of Preventive Medicine, Brigham and Women’s Hospital</json:string><json:string>INSERM Unit 708—Neuroepidemiology and UPMC University Paris 06, Paris, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Research</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Objective To evaluate the relation between Parkinson’s disease and prior use of non-steroidal anti-inflammatory drugs (NSAIDs) in a large cohort of men. Design Case-control analysis nested in the Physicians’ Health Study. Participants 22 007 male physicians aged 40–84 years without indications for or contraindications to regular NSAID use and free of Parkinson’s disease at baseline. Cases and controls were matched by age alone or by age and scores for confounders (comorbidity and indicators of NSAID use). Up to five controls were matched to each of 616 cases by age and 565 cases by age and confounder scores. Setting United States. Main outcome measures Odds of having been exposed to prior non-aspirin NSAID or aspirin use by participants with Parkinson’s disease and by their controls in each case-control set. Results Participants who had ever used non-aspirin NSAIDs had an increased risk of Parkinson’s disease (odds ratio 1.28 (95% CI 1.05 to 1.56) in the age matched group but not in the group also matched on confounder scores (odds ratio 1.17 (0.94 to 1.46)). There was an increased risk of Parkinson’s disease in men who had 1–2 years of regular non-aspirin NSAID use (odds ratio 1.35 (1.07 to 1.70)), a finding that remained significant after matching for confounder scores as well (odds ratio 1.35 (1.05 to 1.75)). In contrast, the significant association of use of non-aspirin NSAIDs for ≥5 years (odds ratio 1.48 (1.05 to 2.09)) in the age matched group was entirely attenuated in the group also matched on confounder scores (1.03 (0.70 to 1.53)). There was also a suggestion that men who regularly used aspirin had an increased risk of Parkinson’s disease. Positive associations between non-aspirin NSAID or aspirin and risk of Parkinson’s disease tended to disappear when analyses were limited to drug use ≥5 years before the disease diagnosis. Conclusions This case-control study did not find evidence that NSAID use reduces Parkinson’s disease risk. The positive associations observed between NSAID use and Parkinson’s disease might have been due to confounding by indication as the use was clustered in the few years before disease diagnosis.</abstract><qualityIndicators><score>9.5</score><pdfVersion>1.6</pdfVersion><pdfPageSize>595 x 794 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>1</keywordCount><abstractCharCount>2168</abstractCharCount><pdfWordCount>6079</pdfWordCount><pdfCharCount>39218</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>344</abstractWordCount></qualityIndicators><title>Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study</title><genre><json:string>research-article</json:string></genre><host><volume>342</volume><issn><json:string>0959-8138</json:string></issn><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-5833</json:string></eissn><title>BMJ</title></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1136/bmj.d198</json:string></doi><id>EA84488FD2F1E76778E328DDFA4D82BE58E74696</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/EA84488FD2F1E76778E328DDFA4D82BE58E74696/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/EA84488FD2F1E76778E328DDFA4D82BE58E74696/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/EA84488FD2F1E76778E328DDFA4D82BE58E74696/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>British Medical Journal Publishing Group</publisher><availability><p>BMJ</p></availability><date>2011</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study</title><author corresp="yes"><persName><forename type="first">Jane A</forename><surname>Driver</surname></persName><email>jdriver@partners.org</email><note type="biography">assistant professor of medicine</note><affiliation>assistant professor of medicine</affiliation><affiliation>Geriatric Research, Education and Clinical Center, VA Boston Healthcare System; Boston MA, USA</affiliation><affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</affiliation><affiliation>Massachusetts Veterans Epidemiology Research Information Center, VA Boston Healthcare System</affiliation></author><author><persName><forename type="first">Giancarlo</forename><surname>Logroscino</surname></persName><note type="biography">associate professor of neurology</note><affiliation>associate professor of neurology</affiliation><affiliation>Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy</affiliation></author><author><persName><forename type="first">Linda</forename><surname>Lu</surname></persName><note type="biography">instructor of medicine</note><affiliation>instructor of medicine</affiliation><affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</affiliation></author><author><persName><forename type="first">J Michael</forename><surname>Gaziano</surname></persName><note type="biography">professor of medicine</note><affiliation>professor of medicine</affiliation><affiliation>Geriatric Research, Education and Clinical Center, VA Boston Healthcare System; Boston MA, USA</affiliation><affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</affiliation><affiliation>Massachusetts Veterans Epidemiology Research Information Center, VA Boston Healthcare System</affiliation><affiliation>Division of Preventive Medicine, Brigham and Women’s Hospital</affiliation></author><author><persName><forename type="first">Tobias</forename><surname>Kurth</surname></persName><note type="biography">director of research</note><affiliation>director of research</affiliation><affiliation>Division of Preventive Medicine, Brigham and Women’s Hospital</affiliation><affiliation>INSERM Unit 708—Neuroepidemiology and UPMC University Paris 06, Paris, France</affiliation></author></analytic><monogr><title level="j">BMJ</title><title level="j" type="abbrev">BMJ</title><idno type="pISSN">0959-8138</idno><idno type="eISSN">1468-5833</idno><imprint><publisher>British Medical Journal Publishing Group</publisher><date type="published" when="2011"></date><biblScope unit="volume">342</biblScope></imprint></monogr><idno type="istex">EA84488FD2F1E76778E328DDFA4D82BE58E74696</idno><idno type="DOI">10.1136/bmj.d198</idno><idno type="href">bmj-342-bmj-d198.pdf</idno><idno type="ArticleID">drij761171</idno><idno type="local">bmj;342/jan20_1/d198</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Objective To evaluate the relation between Parkinson’s disease and prior use of non-steroidal anti-inflammatory drugs (NSAIDs) in a large cohort of men. Design Case-control analysis nested in the Physicians’ Health Study. Participants 22 007 male physicians aged 40–84 years without indications for or contraindications to regular NSAID use and free of Parkinson’s disease at baseline. Cases and controls were matched by age alone or by age and scores for confounders (comorbidity and indicators of NSAID use). Up to five controls were matched to each of 616 cases by age and 565 cases by age and confounder scores. Setting United States. Main outcome measures Odds of having been exposed to prior non-aspirin NSAID or aspirin use by participants with Parkinson’s disease and by their controls in each case-control set. Results Participants who had ever used non-aspirin NSAIDs had an increased risk of Parkinson’s disease (odds ratio 1.28 (95% CI 1.05 to 1.56) in the age matched group but not in the group also matched on confounder scores (odds ratio 1.17 (0.94 to 1.46)). There was an increased risk of Parkinson’s disease in men who had 1–2 years of regular non-aspirin NSAID use (odds ratio 1.35 (1.07 to 1.70)), a finding that remained significant after matching for confounder scores as well (odds ratio 1.35 (1.05 to 1.75)). In contrast, the significant association of use of non-aspirin NSAIDs for ≥5 years (odds ratio 1.48 (1.05 to 2.09)) in the age matched group was entirely attenuated in the group also matched on confounder scores (1.03 (0.70 to 1.53)). There was also a suggestion that men who regularly used aspirin had an increased risk of Parkinson’s disease. Positive associations between non-aspirin NSAID or aspirin and risk of Parkinson’s disease tended to disappear when analyses were limited to drug use ≥5 years before the disease diagnosis. Conclusions This case-control study did not find evidence that NSAID use reduces Parkinson’s disease risk. The positive associations observed between NSAID use and Parkinson’s disease might have been due to confounding by indication as the use was clustered in the few years before disease diagnosis.</p></abstract></profileDesc><revisionDesc><change when="2011">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-14">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/EA84488FD2F1E76778E328DDFA4D82BE58E74696/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">bmj</journal-id><journal-id journal-id-type="nlm-ta">BMJ</journal-id><journal-id journal-id-type="publisher-id">bmj</journal-id><journal-title>BMJ</journal-title><abbrev-journal-title abbrev-type="publisher">BMJ</abbrev-journal-title><issn pub-type="ppub">0959-8138</issn><issn pub-type="epub">1468-5833</issn><publisher><publisher-name>British Medical Journal Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">drij761171</article-id><article-id pub-id-type="doi">10.1136/bmj.d198</article-id><article-id pub-id-type="other">bmj;342/jan20_1/d198</article-id><article-id pub-id-type="other">bmj;bmj.d198</article-id><article-id pub-id-type="other">jan20_1</article-id><article-id pub-id-type="other">bmj.d198</article-id><article-id pub-id-type="other">bmj.d198</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Driver</surname><given-names>Jane A</given-names></name><role>assistant professor of medicine</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Logroscino</surname><given-names>Giancarlo</given-names></name><role>associate professor of neurology</role><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Lu</surname><given-names>Linda</given-names></name><role>instructor of medicine</role><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Gaziano</surname><given-names>J Michael</given-names></name><role>professor of medicine</role><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Kurth</surname><given-names>Tobias</given-names></name><role>director of research</role><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref></contrib><aff id="aff1"><label>1</label>Geriatric Research, Education and Clinical Center, VA Boston Healthcare System; Boston MA, USA</aff><aff id="aff2"><label>2</label>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</aff><aff id="aff3"><label>3</label>Massachusetts Veterans Epidemiology Research Information Center, VA Boston Healthcare System </aff><aff id="aff4"><label>4</label>Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy</aff><aff id="aff5"><label>5</label>Division of Preventive Medicine, Brigham and Women’s Hospital</aff><aff id="aff6"><label>6</label>INSERM Unit 708—Neuroepidemiology and UPMC University Paris 06, Paris, France</aff></contrib-group><author-notes><corresp>Correspondence to: J A Driver, Division of Aging, Brigham and Women’s Hospital, 1620 Tremont Street, Boston, MA 02120, USA <email>jdriver@partners.org</email></corresp></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub-original"><year>2011</year></pub-date><volume>342</volume><volume-id pub-id-type="other">342</volume-id><volume-id pub-id-type="other">342</volume-id><elocation-id>d198</elocation-id><history><date date-type="accepted"><day>19</day><month>October</month><year>2010</year></date></history><permissions><copyright-statement>© Driver et al 2011</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Driver et al</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: <ext-link xlink:href="http://creativecommons.org/licenses/by-nc/2.0/" ext-link-type="uri">http://creativecommons.org/licenses/by-nc/2.0/</ext-link> and <ext-link xlink:href="http://creativecommons.org/licenses/by-nc/2.0/legalcode" ext-link-type="uri">http://creativecommons.org/licenses/by-nc/2.0/legalcode</ext-link>.</p></license></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="bmj-342-bmj-d198.pdf"></self-uri><abstract><p><bold>Objective</bold> To evaluate the relation between Parkinson’s disease and prior use of non-steroidal anti-inflammatory drugs (NSAIDs) in a large cohort of men.</p><p><bold>Design</bold> Case-control analysis nested in the Physicians’ Health Study. </p><p><bold>Participants</bold> 22 007 male physicians aged 40–84 years without indications for or contraindications to regular NSAID use and free of Parkinson’s disease at baseline. Cases and controls were matched by age alone or by age and scores for confounders (comorbidity and indicators of NSAID use). Up to five controls were matched to each of 616 cases by age and 565 cases by age and confounder scores.</p><p><bold>Setting</bold> United States.</p><p><bold>Main outcome measures</bold> Odds of having been exposed to prior non-aspirin NSAID or aspirin use by participants with Parkinson’s disease and by their controls in each case-control set.</p><p><bold>Results</bold> Participants who had ever used non-aspirin NSAIDs had an increased risk of Parkinson’s disease (odds ratio 1.28 (95% CI 1.05 to 1.56) in the age matched group but not in the group also matched on confounder scores (odds ratio 1.17 (0.94 to 1.46)). There was an increased risk of Parkinson’s disease in men who had 1–2 years of regular non-aspirin NSAID use (odds ratio 1.35 (1.07 to 1.70)), a finding that remained significant after matching for confounder scores as well (odds ratio 1.35 (1.05 to 1.75)). In contrast, the significant association of use of non-aspirin NSAIDs for ≥5 years (odds ratio 1.48 (1.05 to 2.09)) in the age matched group was entirely attenuated in the group also matched on confounder scores (1.03 (0.70 to 1.53)). There was also a suggestion that men who regularly used aspirin had an increased risk of Parkinson’s disease. Positive associations between non-aspirin NSAID or aspirin and risk of Parkinson’s disease tended to disappear when analyses were limited to drug use ≥5 years before the disease diagnosis.</p><p><bold>Conclusions</bold> This case-control study did not find evidence that NSAID use reduces Parkinson’s disease risk. The positive associations observed between NSAID use and Parkinson’s disease might have been due to confounding by indication as the use was clustered in the few years before disease diagnosis.</p></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Jane A</namePart><namePart type="family">Driver</namePart><affiliation>Geriatric Research, Education and Clinical Center, VA Boston Healthcare System; Boston MA, USA</affiliation><affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</affiliation><affiliation>Massachusetts Veterans Epidemiology Research Information Center, VA Boston Healthcare System</affiliation><affiliation>E-mail: jdriver@partners.org</affiliation><description>assistant professor of medicine</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giancarlo</namePart><namePart type="family">Logroscino</namePart><affiliation>Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy</affiliation><description>associate professor of neurology</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Linda</namePart><namePart type="family">Lu</namePart><affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</affiliation><description>instructor of medicine</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J Michael</namePart><namePart type="family">Gaziano</namePart><affiliation>Geriatric Research, Education and Clinical Center, VA Boston Healthcare System; Boston MA, USA</affiliation><affiliation>Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston</affiliation><affiliation>Massachusetts Veterans Epidemiology Research Information Center, VA Boston Healthcare System</affiliation><affiliation>Division of Preventive Medicine, Brigham and Women’s Hospital</affiliation><description>professor of medicine</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tobias</namePart><namePart type="family">Kurth</namePart><affiliation>Division of Preventive Medicine, Brigham and Women’s Hospital</affiliation><affiliation>INSERM Unit 708—Neuroepidemiology and UPMC University Paris 06, Paris, France</affiliation><description>director of research</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><originInfo><publisher>British Medical Journal Publishing Group</publisher><dateIssued encoding="w3cdtf">2011</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Objective To evaluate the relation between Parkinson’s disease and prior use of non-steroidal anti-inflammatory drugs (NSAIDs) in a large cohort of men. Design Case-control analysis nested in the Physicians’ Health Study. Participants 22 007 male physicians aged 40–84 years without indications for or contraindications to regular NSAID use and free of Parkinson’s disease at baseline. Cases and controls were matched by age alone or by age and scores for confounders (comorbidity and indicators of NSAID use). Up to five controls were matched to each of 616 cases by age and 565 cases by age and confounder scores. Setting United States. Main outcome measures Odds of having been exposed to prior non-aspirin NSAID or aspirin use by participants with Parkinson’s disease and by their controls in each case-control set. Results Participants who had ever used non-aspirin NSAIDs had an increased risk of Parkinson’s disease (odds ratio 1.28 (95% CI 1.05 to 1.56) in the age matched group but not in the group also matched on confounder scores (odds ratio 1.17 (0.94 to 1.46)). There was an increased risk of Parkinson’s disease in men who had 1–2 years of regular non-aspirin NSAID use (odds ratio 1.35 (1.07 to 1.70)), a finding that remained significant after matching for confounder scores as well (odds ratio 1.35 (1.05 to 1.75)). In contrast, the significant association of use of non-aspirin NSAIDs for ≥5 years (odds ratio 1.48 (1.05 to 2.09)) in the age matched group was entirely attenuated in the group also matched on confounder scores (1.03 (0.70 to 1.53)). There was also a suggestion that men who regularly used aspirin had an increased risk of Parkinson’s disease. Positive associations between non-aspirin NSAID or aspirin and risk of Parkinson’s disease tended to disappear when analyses were limited to drug use ≥5 years before the disease diagnosis. Conclusions This case-control study did not find evidence that NSAID use reduces Parkinson’s disease risk. The positive associations observed between NSAID use and Parkinson’s disease might have been due to confounding by indication as the use was clustered in the few years before disease diagnosis.</abstract><relatedItem type="host"><titleInfo><title>BMJ</title></titleInfo><titleInfo type="abbreviated"><title>BMJ</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0959-8138</identifier><identifier type="eISSN">1468-5833</identifier><identifier type="PublisherID">bmj</identifier><identifier type="PublisherID-hwp">bmj</identifier><identifier type="PublisherID-nlm-ta">BMJ</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>342</number></detail></part></relatedItem><identifier type="istex">EA84488FD2F1E76778E328DDFA4D82BE58E74696</identifier><identifier type="DOI">10.1136/bmj.d198</identifier><identifier type="href">bmj-342-bmj-d198.pdf</identifier><identifier type="ArticleID">drij761171</identifier><identifier type="local">bmj;342/jan20_1/d198</identifier><accessCondition type="use and reproduction" contentType="open-access">This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.</accessCondition><recordInfo><recordContentSource>BMJ</recordContentSource><recordOrigin>Driver et al</recordOrigin></recordInfo></mods></metadata><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/EA84488FD2F1E76778E328DDFA4D82BE58E74696/annexes/jpeg</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000172 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000172 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:EA84488FD2F1E76778E328DDFA4D82BE58E74696
|texte= Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study
}}
| This area was generated with Dilib version V0.6.23. |  |